Baseline predictors of BCVA 20/40 in ranibizumab-treated patients were good BCVA , submacular fluid , no cardiovascular disease , no scatter photocoagulation , and male gender , whereas in sham-treated patients , they were mild increase in CFT , presence of hard exudates in center subfield , and absence of renal disease .